Company profile: Spectrum Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of novel, targeted biopharmaceuticals focused on acquiring, developing, and commercializing therapies in oncology and hematology. Products include ROLVEDON (reduces severe neutropenia in non-myeloid malignancies on myelosuppressive drugs), SYMPAZAN (Lennox-Gastaut seizures), SPRIX (short-term pain), Otrexup (RA, psoriasis), Cambia (acute migraine), and INDOCIN (RA, AS, OA).
Products and services
- ROLVEDON (eflapegrastim-xnst) injection: Subcutaneous biologic that reduces the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs
- INDOCIN (indomethacin) Suppositories: Rectal dosage form delivering indomethacin to treat moderate to severe rheumatoid arthritis, ankylosing spondylitis, and osteoarthritis
- Otrexup (methotrexate) injection: Subcutaneous methotrexate formulation for the treatment of severe, active rheumatoid arthritis and psoriasis, administered via an injection route
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Spectrum Pharmaceuticals
Sierra Oncology
HQ: United States
Website
- Description: Provider of targeted cancer therapeutics in clinical development, focused on rare forms of cancer. Leverages deep scientific expertise to identify compounds that target root causes of disease and advances therapies using an evidence-based approach.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sierra Oncology company profile →
Rain Oncology
HQ: United States
Website
- Description: Provider of precision oncology therapies targeting oncogenic drivers, developing milademetan, an oral small molecule inhibitor of the p53-MDM2 complex for various cancers. Clinical programs include MANTRA (Phase 3 in dedifferentiated liposarcoma), MANTRA-2 (Phase 2 in TP53 wildtype/MDM2-amplified solid tumors), and MANTRA-4 (Phase 1/2 with atezolizumab in CDKN2A loss, TP53 wildtype tumors).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rain Oncology company profile →
OncoVista Innovative Therapies
HQ: United States
Website
- Description: Provider of anticancer therapy development utilizing tumor-associated biomarkers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OncoVista Innovative Therapies company profile →
Angiex
HQ: United States
Website
- Description: Provider of vascular-targeted biotherapeutics, developing TM4SF1-directed antibody-drug conjugates for solid tumors, including AGX101, an antibody–microtubule inhibitor conjugate entering Phase 1 to target tumor cells and tumor vascular endothelium; a Nuclear Delivery Platform with antibodies, site-specific conjugation, and linkers for nucleus/cytosol delivery; and a preclinical ND-ADC pipeline using small molecule and protein degrader payloads.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Angiex company profile →
Novelos Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical research, development, and commercialization focused on oxidized glutathione.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Novelos Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Spectrum Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Spectrum Pharmaceuticals
2.2 - Growth funds investing in similar companies to Spectrum Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Spectrum Pharmaceuticals
4.2 - Public trading comparable groups for Spectrum Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →